Table 2.
Enavatuzumab inhibits breast cancer cell growth in vitro
| Subtype | TweakR expression | Inhibition of proliferation by enavatuzumab | ||||||
|---|---|---|---|---|---|---|---|---|
| Soluble | +xlinker | Immobilized | ||||||
| 10 μg/mL | EC50 (μg/mL) | 10 μg/mL | EC50 (μg/mL) | 10 μg/mL | EC50 (μg/mL) | |||
| BT20 | B | 7.5 | – | − | − | − | + | 1.21 |
| BT474 | H | 2.3 | − | − | − | − | ± | 1.85 |
| BT483 | L | 2.5 | − | − | + | 2.30 | +++ | 1.48 |
| BT549 | B | 4.7 | + | 1.32 | ++ | 0.20 | ++ | 0.72 |
| Cama1 | L | 3.8 | − | − | + | 1.57 | ++ | 2.16 |
| DU4475 | B | 1.5 | − | − | − | − | − | − |
| HCC1143 | B | 3.4 | − | − | + | 0.18 | + | 1.31 |
| HCC1428 | L | 1.4 | − | − | ± | 1.85 | + | 1.77 |
| HCC1500 | B | 2.7 | − | − | ± | 1.75 | +++ | 1.60 |
| HCC1569 | H | 2.8 | − | − | ± | 0.32 | − | − |
| HCC1937 | B | 5.3 | ± | 4.46 | + | 0.42 | + | 2.38 |
| HCC38 | B | 6.6 | + | 0.31 | ++ | 0.31 | ++ | 1.53 |
| HCC70 | B | 2.4 | − | − | + | 0.23 | ± | 2.30 |
| Hs578T | B | 4.8 | − | − | − | − | − | − |
| MB231 variant | B | 8.3 | + | 2.98 | + | 0.15 | ++ | 1.33 |
| MCF7 | L | 5.8 | − | − | ± | 0.41 | + | 1.27 |
| MDA-MB157 | B | 5.9 | − | − | ± | 0.06 | + | 1.20 |
| MDA-MB175 VII | L | 1.4 | − | − | − | − | − | − |
| MDA-MB231 | B | 10.3 | + | 1.99 | + | 0.35 | + | 1.02 |
| MDA-MB361 | H | 4.7 | − | − | − | − | − | − |
| MDA-MB453 | H | 2.6 | − | − | + | 1.04 | + | 2.59 |
| MDA-MB468 | B | 8.8 | + | 0.31 | + | 0.52 | +++ | 1.10 |
| MX1 | B | 4.7 | − | − | + | 0.71 | ++ | 1.08 |
| SKBR3 | H | 2.3 | ± | 1.93 | + | 0.50 | ++ | 1.36 |
| T47D | L | 1.8 | − | − | − | − | − | − |
| ZR-75-1 | L | 1.9 | − | − | − | − | + | 1.48 |
| ZR-75-30 | H | 1.6 | − | − | − | − | − | − |
B basal, L luminal, H HER2+
TweakR expression: fold increase of TweakR versus control
Inhibition score: − <10 %, ±10–20 %, +20–50 %, ++50–75 %, +++ >75 %, nt not tested